When Should Statins Be Stopped?

Area of Science:

• Infectious Diseases
• Pharmacology
• Dermatology

Background:

• Mycobacterium chelonae, a non-tuberculous mycobacterium, can cause skin infections in immunocompetent individuals.
• Drug interactions involving statins can lead to serious adverse events like rhabdomyolysis.
• Dyslipidaemia is a common condition often managed with statin therapy.

Purpose of the Study:

• To report a case of skin infection by Mycobacterium chelonae.
• To highlight the potential for statin-induced rhabdomyolysis resulting from drug interactions.
• To emphasize the importance of considering drug metabolism pathways in clinical practice.

Main Methods:

• Case report detailing a patient's presentation and treatment.
• Review of relevant literature on Mycobacterium chelonae infections and statin-drug interactions.
• Analysis of the pharmacokinetic interactions involved.

Main Results:

• The patient developed a skin infection caused by Mycobacterium chelonae.
• The patient experienced statin-induced rhabdomyolysis while on a regimen including clarithromycin, ciprofloxacin, and simvastatin.
• Clarithromycin was identified as a potential inhibitor of cytochrome P450 3A4 and organic anion transporting polypeptide 1B1, affecting simvastatin metabolism.

Conclusions:

• Skin infections with Mycobacterium chelonae are an increasing global concern, even in immunocompetent individuals.
• Statin-induced rhabdomyolysis is a significant and preventable outcome of drug-drug interactions.
• Understanding drug metabolism, particularly the inhibition of key enzymes like CYP3A4 and OATP1B1, is crucial for avoiding adverse drug events.